GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (NAS:BOLT) » Definitions » Earnings per Share (Diluted)

Bolt Biotherapeutics (Bolt Biotherapeutics) Earnings per Share (Diluted) : $-1.83 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Bolt Biotherapeutics Earnings per Share (Diluted)?

Bolt Biotherapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.47. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.83.

Bolt Biotherapeutics's EPS (Basic) for the three months ended in Dec. 2023 was $-0.47. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.83.

Bolt Biotherapeutics's EPS without NRI for the three months ended in Dec. 2023 was $-0.47. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.83.

During the past 3 years, the average EPS without NRIGrowth Rate was -6.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was -8.60% per year.

During the past 6 years, Bolt Biotherapeutics's highest 3-Year average EPS without NRI Growth Rate was -2.70% per year. The lowest was -31.90% per year. And the median was -6.00% per year.


Bolt Biotherapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for Bolt Biotherapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bolt Biotherapeutics Earnings per Share (Diluted) Chart

Bolt Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial -2.18 -1.91 -2.97 -2.36 -1.83

Bolt Biotherapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.53 -0.45 -0.48 -0.43 -0.47

Competitive Comparison of Bolt Biotherapeutics's Earnings per Share (Diluted)

For the Biotechnology subindustry, Bolt Biotherapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bolt Biotherapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Bolt Biotherapeutics's PE Ratio falls into.



Bolt Biotherapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Bolt Biotherapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-69.197-0)/37.812
=-1.83

Bolt Biotherapeutics's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-17.903-0)/37.943
=-0.47

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Bolt Biotherapeutics  (NAS:BOLT) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Bolt Biotherapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Bolt Biotherapeutics (Bolt Biotherapeutics) Business Description

Traded in Other Exchanges
Address
900 Chesapeake Drive, Redwood, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
Executives
William P. Quinn officer: Chief Financial Officer SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Edgar Engleman director 575 HIGH STREET, STE 201, PALO ALTO CA 94301
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Laura Berner director C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Brian O'callaghan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Frank D. Lee director C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Kathleen Laporte director
Miller Richard A Md director PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Mahendra Shah director 2250 HOLCOMBE BLVD, HOUSTON TX 77030
Grant Yonehiro officer: Chief Business Officer C/O MAXYGEN, INC., 515 GALVESTON DRIVE, REDWOOD CITY CA 94063
Randall C Schatzman director, officer: Chief Executive Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
David Dornan officer: Chief Scientific Officer C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Edith A. Perez officer: Chief Medical Officer C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTONE DRIVE, REDWOOD CITY CA 94063

Bolt Biotherapeutics (Bolt Biotherapeutics) Headlines

From GuruFocus

Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference

By Value_Insider Value_Insider 11-01-2022